Cancer Therapeutics

1. Abraxane patent expiration

Treatment: Treatment of lung cancer; Treatment of breast cancer; Treatment of pancreatic

ABRAXANE's oppositions filed in EPO
ABRAXANE IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7923536 BRISTOL-MYERS Compositions and methods of delivery of pharmacological agents
Dec, 2023

(10 months ago)

US8138229 BRISTOL-MYERS Compositions and methods of delivery of pharmacological agents
Dec, 2023

(10 months ago)

US8853260 BRISTOL-MYERS Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
Oct, 2020

(4 years ago)

US8314156 BRISTOL-MYERS Compositions and methods of delivery of pharmacological agents
Dec, 2023

(10 months ago)

USRE41884 BRISTOL-MYERS Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
Aug, 2016

(8 years ago)

US6537579 BRISTOL-MYERS Compositions and methods for administration of pharmacologically active compounds
Feb, 2013

(11 years ago)

US6096331 BRISTOL-MYERS Methods and compositions useful for administration of chemotherapeutic agents
Feb, 2013

(11 years ago)

US5439686 BRISTOL-MYERS Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
Feb, 2013

(11 years ago)

US8034375 BRISTOL-MYERS Combinations and modes of administration of therapeutic agents and combination therapy
Aug, 2026

(1 year, 9 months from now)

US9511046 BRISTOL-MYERS Methods of treating pancreatic cancer
Jan, 2034

(9 years from now)

US9393318 BRISTOL-MYERS Methods of treating cancer
Mar, 2032

(7 years from now)

US9597409 BRISTOL-MYERS Methods of treating cancer
Mar, 2032

(7 years from now)

US8268348 BRISTOL-MYERS Combinations and modes of administration of therapeutic agents and combination therapy
Feb, 2026

(1 year, 4 months from now)

US9101543 BRISTOL-MYERS Combinations and modes of administration of therapeutic agents and combination therapy
Feb, 2026

(1 year, 4 months from now)

US7758891 BRISTOL-MYERS Combinations and modes of administration of therapeutic agents and combination therapy
Feb, 2026

(1 year, 4 months from now)

US7820788 BRISTOL-MYERS Compositions and methods of delivery of pharmacological agents
Oct, 2024

(12 days from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-658) Oct 11, 2015
New Indication(I-676) Sep 06, 2016
Orphan Drug Exclusivity(ODE) Sep 06, 2020
Orphan Drug Exclusivity(ODE-52) Sep 06, 2020
M(M-14) Dec 06, 2022
Pediatric Exclusivity(PED) Jun 06, 2023

Drugs and Companies using PACLITAXEL ingredient

Market Authorisation Date: 07 January, 2005

Dosage: POWDER

How can I launch a generic of ABRAXANE before it's drug patent expiration?
More Information on Dosage

ABRAXANE family patents

Family Patents

2. Abstral patent expiration

Treatment: Management of breakthrough pain in patients with cancer

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7910132 SENTYNL THERAPS INC Pharmaceutical composition for the treatment of acute disorders
Sep, 2019

(5 years ago)

US6761910 SENTYNL THERAPS INC Pharmaceutical composition for the treatment of acute disorders
Sep, 2019

(5 years ago)

US6759059 SENTYNL THERAPS INC Fentanyl composition for the treatment of acute pain
Sep, 2019

(5 years ago)




Drugs and Companies using FENTANYL CITRATE ingredient

Market Authorisation Date: 07 January, 2011

Dosage: TABLET

How can I launch a generic of ABSTRAL before it's drug patent expiration?
More Information on Dosage

ABSTRAL family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Afinitor patent expiration

Treatment: Treatment of advanced hormone receptor positive, her2-negative breast cancer in combination with exemestane after failure of treatment with ...

AFINITOR's oppositions filed in EPO
Can you believe AFINITOR received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8436010 NOVARTIS Treatment of solid tumors with rapamycin derivatives
Feb, 2022

(2 years ago)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-630) Oct 29, 2013
New Chemical Entity Exclusivity(NCE) Mar 30, 2014
New Indication(I-638) May 05, 2014
New Indication(I-650) Apr 26, 2015
New Indication(I-655) Jul 20, 2015
Pediatric Exclusivity(PED) Apr 29, 2018
Orphan Drug Exclusivity(ODE) Apr 26, 2019
Orphan Drug Exclusivity(ODE-11) May 05, 2018
New Indication(I-724) Feb 26, 2019
Orphan Drug Exclusivity(ODE-24) Apr 26, 2019
Orphan Drug Exclusivity(ODE-108) Feb 26, 2023

Drugs and Companies using EVEROLIMUS ingredient

NCE-1 date: 26 October, 2014

Market Authorisation Date: 09 July, 2010

Dosage: TABLET

How can I launch a generic of AFINITOR before it's drug patent expiration?
More Information on Dosage

AFINITOR family patents

Family Patents

4. Akeega patent expiration

Treatment: A method for treating metastatic castration-resistant prostate cancer (mcrpc), wherein the Read More

AKEEGA's oppositions filed in EPO
AKEEGA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11992486 JANSSEN BIOTECH Methods of treating prostate cancer
Jul, 2037

(12 years from now)

US11986469 JANSSEN BIOTECH Methods of treating prostate cancer
Jul, 2037

(12 years from now)

US11986468 JANSSEN BIOTECH Methods of treating prostate cancer
Jul, 2037

(12 years from now)

US8071579 JANSSEN BIOTECH DNA damage repair inhibitors for the treatment of cancer
Aug, 2027

(2 years from now)

US8143241 JANSSEN BIOTECH DNA damage repair inhibitors for treatment of cancer
Aug, 2027

(2 years from now)

US8859562 JANSSEN BIOTECH Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer
Aug, 2031

(6 years from now)

US11207311 JANSSEN BIOTECH Method of treating prostate cancer
Jul, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 11, 2026

Drugs and Companies using ABIRATERONE ACETATE; NIRAPARIB TOSYLATE ingredient

Market Authorisation Date: 11 August, 2023

Dosage: TABLET

More Information on Dosage

AKEEGA family patents

Family Patents

5. Akynzeo patent expiration

Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic

AKYNZEO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9403772 HELSINN HLTHCARE 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
May, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10208073 HELSINN HLTHCARE Solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-IUM-(fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone as a neurokinin receptor modulator
May, 2032

(7 years from now)

US8895586 HELSINN HLTHCARE Methods of treating emesis
May, 2032

(7 years from now)

US9186357 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Nov, 2030

(6 years from now)

US10828297 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Dec, 2030

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 19, 2023

Drugs and Companies using FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE ingredient

NCE-1 date: 19 April, 2022

Market Authorisation Date: 19 April, 2018

Dosage: POWDER; SOLUTION

How can I launch a generic of AKYNZEO before it's drug patent expiration?
More Information on Dosage

AKYNZEO family patents

Family Patents

6. Akynzeo patent expiration

Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of Read More

AKYNZEO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9943515 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Nov, 2030

(6 years from now)

US8623826 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Nov, 2030

(6 years from now)

US9271975 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Sep, 2031

(6 years from now)

US9186357 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Nov, 2030

(6 years from now)

US10828297 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Dec, 2030

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 19, 2023

Drugs and Companies using NETUPITANT; PALONOSETRON HYDROCHLORIDE ingredient

NCE-1 date: 10 October, 2018

Market Authorisation Date: 10 October, 2014

Dosage: CAPSULE

More Information on Dosage

AKYNZEO family patents

Family Patents

7. Alunbrig patent expiration

Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)

ALUNBRIG's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10385078 TAKEDA PHARMS USA Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine
Nov, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9611283 TAKEDA PHARMS USA Methods for inhibiting cell proliferation in ALK-driven cancers
Apr, 2034

(9 years from now)

US9273077 TAKEDA PHARMS USA Phosphorus derivatives as kinase inhibitors
May, 2029

(4 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 28, 2022
New Indication(I-847) May 22, 2023
Orphan Drug Exclusivity(ODE) Apr 28, 2024
Orphan Drug Exclusivity(ODE-142) Apr 28, 2024
Orphan Drug Exclusivity(ODE-300) May 22, 2027

Drugs and Companies using BRIGATINIB ingredient

NCE-1 date: 28 April, 2021

Market Authorisation Date: 28 April, 2017

Dosage: TABLET

More Information on Dosage

ALUNBRIG family patents

Family Patents

8. Augtyro patent expiration

Treatment: Treatment of adult patients with locally advanced or metastatic ros1-positive non-small cell lung cancer (nsclc)

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11452725 BRISTOL Chiral diaryl macrocycles and uses thereof
Jul, 2036

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 15, 2028
ODE*(ODE*) Nov 15, 2030
Orphan Drug Exclusivity(ODE-455) Nov 15, 2030
Orphan Drug Exclusivity(ODE-483) Jun 13, 2031
Orphan Drug Exclusivity(ODE-488) Jun 13, 2031

Drugs and Companies using REPOTRECTINIB ingredient

NCE-1 date: 16 November, 2027

Market Authorisation Date: 15 November, 2023

Dosage: CAPSULE

More Information on Dosage

AUGTYRO family patents

Family Patents

9. Axumin patent expiration

Treatment: Positron emission tomography diagnostic agent in adults with suspected prostate cancer recurrence based on elevated blood prostate specific ...

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10124079 BLUE EARTH Imaging of metastatic or recurrent cancer
Dec, 2035

(11 years from now)

US11980674 BLUE EARTH Imaging of metastatic or recurrent cancer
Apr, 2042

(17 years from now)

US10716868 BLUE EARTH Imaging of metastatic or recurrent cancer
Dec, 2035

(11 years from now)

US10967077 BLUE EARTH Imaging of metastatic or recurrent cancer
Dec, 2035

(11 years from now)

US10933147 BLUE EARTH Imaging of metastatic or recurrent cancer
Dec, 2035

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 27, 2021

Drugs and Companies using FLUCICLOVINE F-18 ingredient

NCE-1 date: 27 May, 2020

Market Authorisation Date: 27 May, 2016

Dosage: SOLUTION

More Information on Dosage

AXUMIN family patents

Family Patents

10. Braftovi patent expiration

Treatment: Braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8541575 ARRAY BIOPHARMA INC 3,4-diarylpyrazoles as protein kinase inhibitors
Feb, 2030

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10258622 ARRAY BIOPHARMA INC Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate
Nov, 2032

(8 years from now)

US9474754 ARRAY BIOPHARMA INC Pharmaceutical combinations comprising a B-RAF inhibitor, and EGFR inhibitor and optionally a PI3K-α inhibitor
Aug, 2033

(8 years from now)

US9314464 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Jul, 2031

(6 years from now)

US10005761 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(5 years from now)

US9850230 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(5 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-826) Apr 08, 2023
New Chemical Entity Exclusivity(NCE) Jun 27, 2023
Orphan Drug Exclusivity(ODE-194) Jun 27, 2025
New Indication(I-928) Oct 11, 2026
Orphan Drug Exclusivity(ODE-445) Oct 11, 2030

Drugs and Companies using ENCORAFENIB ingredient

NCE-1 date: 27 June, 2022

Market Authorisation Date: 27 June, 2018

Dosage: CAPSULE

How can I launch a generic of BRAFTOVI before it's drug patent expiration?
More Information on Dosage

BRAFTOVI family patents

Family Patents

11. Cabometyx patent expiration

Treatment: Treatment of differentiated thyroid cancer that has progressed following prior vegfr-targeted therapy

CABOMETYX's oppositions filed in EPO
Can you believe CABOMETYX received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8877776 EXELIXIS INC (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
Oct, 2030

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11098015 EXELIXIS INC Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
Jan, 2030

(5 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 29, 2017
New Product(NP) Apr 25, 2019
New Indication(I-760) Dec 19, 2020
New Indication(I-792) Jan 14, 2022
New Indication(I-854) Jan 22, 2024
New Indication(I-873) Sep 17, 2024
Orphan Drug Exclusivity(ODE-227) Jan 14, 2026
Orphan Drug Exclusivity(ODE-375) Sep 17, 2028

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

NCE-1 date: 29 November, 2016

Market Authorisation Date: 25 April, 2016

Dosage: TABLET

How can I launch a generic of CABOMETYX before it's drug patent expiration?
More Information on Dosage

CABOMETYX family patents

Family Patents

12. Caprelsa patent expiration

Treatment: For use in patients having symptomatic or progressive medullary thyroid cancer, with unresectable locally advanced or metastatic disease

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8642608 GENZYME CORP Quinazoline derivatives as VEGF inhibitors
Feb, 2022

(2 years ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 06, 2016
Orphan Drug Exclusivity(ODE) Apr 06, 2018
Orphan Drug Exclusivity(ODE-9) Apr 06, 2018

Drugs and Companies using VANDETANIB ingredient

NCE-1 date: 07 April, 2015

Market Authorisation Date: 06 April, 2011

Dosage: TABLET

More Information on Dosage

CAPRELSA family patents

Family Patents

13. Cinvanti patent expiration

Treatment: Treatment of nausea and vomiting, including the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly or moderately emetogenic Read More

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9808465 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(10 years from now)

US10953018 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(10 years from now)

US9974794 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(10 years from now)

US9561229 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(10 years from now)

US10624850 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(10 years from now)




Drugs and Companies using APREPITANT ingredient

Market Authorisation Date: 09 November, 2017

Dosage: EMULSION

How can I launch a generic of CINVANTI before it's drug patent expiration?
More Information on Dosage

CINVANTI family patents

Family Patents

14. Cometriq patent expiration

Treatment: Method of treating medullary thyroid cancer

COMETRIQ's oppositions filed in EPO
Can you believe COMETRIQ received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8877776 EXELIXIS (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
Oct, 2030

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11098015 EXELIXIS Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
Jan, 2030

(5 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 29, 2017
Orphan Drug Exclusivity(ODE) Nov 29, 2019
Orphan Drug Exclusivity(ODE-33) Nov 29, 2019

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

NCE-1 date: 29 November, 2016

Market Authorisation Date: 29 November, 2012

Dosage: CAPSULE

More Information on Dosage

COMETRIQ family patents

Family Patents

15. Cosela patent expiration

Treatment: A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a topotecan-containing regimen for extensive- stage small cell lung

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9487530 PHARMACOSMOS Transient protection of normal cells during chemotherapy
Mar, 2034

(9 years from now)

US10085992 PHARMACOSMOS Transient protection of normal cells during chemotherapy
Mar, 2034

(9 years from now)

US11529352 PHARMACOSMOS Preservation of immune response during chemotherapy regimens
Jul, 2039

(14 years from now)

US11717523 PHARMACOSMOS Transient protection of normal cells during chemotherapy
Mar, 2034

(9 years from now)

US10966984 PHARMACOSMOS Transient protection of normal cells during chemotherapy
Mar, 2034

(9 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 12, 2026

Drugs and Companies using TRILACICLIB DIHYDROCHLORIDE ingredient

NCE-1 date: 12 February, 2025

Market Authorisation Date: 12 February, 2021

Dosage: POWDER

More Information on Dosage

COSELA family patents

Family Patents

16. Cytalux patent expiration

Treatment: Cytalux is an optical imaging agent indicated in adult patients with ovarian cancer as an adjunct for intraoperative identification of malig...

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9333270 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(8 years from now)

US9061057 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(8 years from now)

US10881747 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(8 years from now)

US9789208 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-905) Dec 16, 2025
New Chemical Entity Exclusivity(NCE) Nov 29, 2026
Orphan Drug Exclusivity(ODE-390) Nov 29, 2028

Drugs and Companies using PAFOLACIANINE SODIUM ingredient

NCE-1 date: 29 November, 2025

Market Authorisation Date: 29 November, 2021

Dosage: SOLUTION

More Information on Dosage

CYTALUX family patents

Family Patents

17. Docetaxel patent expiration

Treatment: Treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9763880 SHILPA Non-aqueous taxane formulations and methods of using the same
Sep, 2033

(8 years from now)




Drugs and Companies using DOCETAXEL ingredient

Market Authorisation Date: 22 December, 2015

Dosage: INJECTABLE

More Information on Dosage

DOCETAXEL family patents

Family Patents

18. Eligard Kit patent expiration

Treatment: Method of treating cancer; Palliative treatment of prostate cancer

ELIGARD KIT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8470359 TOLMAR Sustained release polymer
Oct, 2023

(a year ago)

US9539333 TOLMAR Sustained release polymer
Nov, 2020

(3 years ago)

US9914802 TOLMAR Sustained release polymer
Nov, 2020

(3 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6773714 TOLMAR Polymeric delivery formulations of leuprolide with improved efficacy
Oct, 2018

(5 years ago)

US5599552 TOLMAR Biodegradable polymer composition
Feb, 2014

(10 years ago)

US6565874 TOLMAR Polymeric delivery formulations of leuprolide with improved efficacy
Oct, 2018

(5 years ago)




Drugs and Companies using LEUPROLIDE ACETATE ingredient

Market Authorisation Date: 13 February, 2003

Dosage: POWDER

More Information on Dosage

ELIGARD KIT family patents

Family Patents

19. Erivedge patent expiration

Treatment: Method of using vismodegib to treat cancer in a mammal

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9278961 GENENTECH Pyridyl inhibitors of hedgehog signalling
Dec, 2028

(4 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 30, 2017

Drugs and Companies using VISMODEGIB ingredient

NCE-1 date: 31 January, 2016

Market Authorisation Date: 30 January, 2012

Dosage: CAPSULE

More Information on Dosage

ERIVEDGE family patents

Family Patents

20. Erleada patent expiration

Treatment: Treatment of non-metastatic, castration-resistant prostate cancer (nm-crpc); Treatment of metastatic castration-sensitive prostate

ERLEADA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8445507 JANSSEN BIOTECH Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
Sep, 2030

(5 years from now)

US9481663 JANSSEN BIOTECH Crystalline forms of an androgen receptor modulator
Jun, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9884054 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Sep, 2033

(8 years from now)

US8802689 JANSSEN BIOTECH Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
Mar, 2027

(2 years from now)

US10052314 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Sep, 2033

(8 years from now)

USRE49353 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Sep, 2033

(8 years from now)

US10849888 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Sep, 2033

(8 years from now)

US10702508 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
Apr, 2038

(13 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-808) Sep 17, 2022
New Chemical Entity Exclusivity(NCE) Feb 14, 2023

Drugs and Companies using APALUTAMIDE ingredient

NCE-1 date: 14 February, 2022

Market Authorisation Date: 14 February, 2018

Dosage: TABLET

How can I launch a generic of ERLEADA before it's drug patent expiration?
More Information on Dosage

ERLEADA family patents

Family Patents

21. Exkivity patent expiration

Treatment: Treatment of patients with non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) exon 20 exon insertion mutations ...

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10227342 TAKEDA PHARMS USA Heteroaryl compounds for kinase inhibition
May, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 15, 2026
Orphan Drug Exclusivity(ODE-374) Sep 15, 2028

Drugs and Companies using MOBOCERTINIB SUCCINATE ingredient

NCE-1 date: 15 September, 2025

Market Authorisation Date: 15 September, 2021

Dosage: CAPSULE

More Information on Dosage

EXKIVITY family patents

Family Patents

22. Fentora patent expiration

Treatment: Management of breakthrough pain in patients with cancer

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6974590 CEPHALON Sublingual buccal effervescent
Mar, 2019

(5 years ago)

US6200604 CEPHALON Sublingual buccal effervescent
Mar, 2019

(5 years ago)




Drugs and Companies using FENTANYL CITRATE ingredient

Market Authorisation Date: 25 September, 2006

Dosage: TABLET

How can I launch a generic of FENTORA before it's drug patent expiration?
More Information on Dosage

FENTORA family patents

Family Patents

23. Firmagon patent expiration

Treatment: Method of treating prostate cancer; Treatment of advanced prostate cancer with a...

FIRMAGON's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9415085 FERRING Method of treating prostate cancer with GnRH antagonist
Apr, 2032

(7 years from now)

US9579359 FERRING Method of treating prostate cancer with GnRH antagonist
Feb, 2029

(4 years from now)

US10695398 FERRING Method of treating prostate cancer with GnRH antagonist
Apr, 2032

(7 years from now)

US10973870 FERRING Methods of treating prostate cancer with GnRH antagonist
Feb, 2029

(4 years from now)

US10729739 FERRING Methods of treating prostate cancer with GnRH antagonist
Feb, 2029

(4 years from now)

US11766468 FERRING Method of treating prostate cancer with GnRH antagonist
Apr, 2032

(7 years from now)

US11826397 FERRING Method of treating prostate cancer with GnRH antagonist
Apr, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 24, 2013

Drugs and Companies using DEGARELIX ACETATE ingredient

NCE-1 date: 24 December, 2012

Market Authorisation Date: 24 December, 2008

Dosage: POWDER

How can I launch a generic of FIRMAGON before it's drug patent expiration?
More Information on Dosage

FIRMAGON family patents

Family Patents

24. Fruzaqla patent expiration

Treatment: Treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinoteca...

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10519142 TAKEDA PHARMS USA Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide
Sep, 2035

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11046674 TAKEDA PHARMS USA Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide
Sep, 2035

(10 years from now)

US8212033 TAKEDA PHARMS USA Use of substituted quinazoline compounds in treating angiogenesis-related diseases
May, 2028

(3 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 08, 2028

Drugs and Companies using FRUQUINTINIB ingredient

NCE-1 date: 09 November, 2027

Market Authorisation Date: 08 November, 2023

Dosage: CAPSULE

More Information on Dosage

FRUZAQLA family patents

Family Patents

25. Fulvestrant patent expiration

Treatment: Treatment of hormone receptor positive advanced breast cancer in postmenopausal women

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9271990 FRESENIUS KABI USA Fulvestrant formulations
May, 2034

(9 years from now)

US9833459 FRESENIUS KABI USA Fulvestrant formulations
Feb, 2034

(9 years from now)

US10188663 FRESENIUS KABI USA Fulvestrant formulations
Feb, 2034

(9 years from now)




Drugs and Companies using FULVESTRANT ingredient

Market Authorisation Date: 20 May, 2019

Dosage: SOLUTION

More Information on Dosage

FULVESTRANT family patents

Family Patents

26. Gavreto patent expiration

Treatment: Treatment of adult patients with metastatic rearranged during transfection (ret) fusion-positive non-small cell lung cancer (nsclc) as detec...

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10030005 RIGEL PHARMS Inhibitors of RET
Nov, 2036

(12 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11273160 RIGEL PHARMS RET inhibitor for use in treating cancer having a RET alteration
Apr, 2039

(14 years from now)

US11872192 RIGEL PHARMS RET inhibitor for use in treating cancer having a RET alteration
Apr, 2039

(14 years from now)

US11963958 RIGEL PHARMS RET inhibitor for use in treating cancer having a RET alteration
Apr, 2039

(14 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 04, 2025
Orphan Drug Exclusivity(ODE-318) Sep 04, 2027
Orphan Drug Exclusivity(ODE-340) Dec 01, 2027
Orphan Drug Exclusivity(ODE-341) Dec 01, 2027

Drugs and Companies using PRALSETINIB ingredient

NCE-1 date: 04 September, 2024

Market Authorisation Date: 04 September, 2020

Dosage: CAPSULE

More Information on Dosage

GAVRETO family patents

Family Patents

27. Gilotrif patent expiration

Treatment: Treatment of patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemothe...

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9539258 BOEHRINGER INGELHEIM Quinazoline derivatives for the treatment of cancer diseases
Nov, 2026

(2 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 12, 2018
New Indication(I-730) Apr 15, 2019
Orphan Drug Exclusivity(ODE-50) Jul 12, 2020
New Indication(I-763) Jan 12, 2021
Orphan Drug Exclusivity(ODE) Apr 15, 2023
Orphan Drug Exclusivity(ODE-115) Apr 15, 2023
Orphan Drug Exclusivity(ODE-230) Jan 12, 2025
M(M-276) Apr 07, 2025
Pediatric Exclusivity(PED) Oct 07, 2025

Drugs and Companies using AFATINIB DIMALEATE ingredient

NCE-1 date: 07 October, 2024

Market Authorisation Date: 12 July, 2013

Dosage: TABLET

How can I launch a generic of GILOTRIF before it's drug patent expiration?
More Information on Dosage

GILOTRIF family patents

Family Patents

28. Ibrance patent expiration

Treatment: Palbociclib for hr-pos. her2-neg. advanced or metastatic breast cancer in combo with an aromatase inhibitor in pts as initial endocrine-base...

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7456168 PFIZER 2-(pyridin-2-ylamino)-pyrido[2,3, d]pyrimidin-7-ones
Jan, 2023

(1 year, 8 months ago)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-725) Feb 19, 2019
New Chemical Entity Exclusivity(NCE) Feb 03, 2020

Drugs and Companies using PALBOCICLIB ingredient

NCE-1 date: 03 February, 2019

Market Authorisation Date: 03 February, 2015

Dosage: TABLET; CAPSULE

How can I launch a generic of IBRANCE before it's drug patent expiration?
More Information on Dosage

IBRANCE family patents

Family Patents

29. Illuccix patent expiration

Treatment: Positron emission tomography (pet) of prostate-specific membrane antigen (psma) positive lesions in men with prostate cancer

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11027031 TELIX Kit for radiolabelling
Jul, 2035

(10 years from now)




Drugs and Companies using GALLIUM GA-68 GOZETOTIDE ingredient

Market Authorisation Date: 17 December, 2021

Dosage: POWDER

More Information on Dosage

ILLUCCIX family patents

Family Patents

30. Ixempra Kit patent expiration

Treatment: Method of treating breast cancer by administering ixabepilone; A method of treating a c...

IXEMPRA KIT IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE41911 R-PHARM US LLC Epothilone derivatives
Sep, 2020

(4 years ago)

USRE41393 R-PHARM US LLC Treatment of refractory tumors using epothilone derivatives
Feb, 2022

(2 years ago)

US6670384 R-PHARM US LLC Methods of administering epothilone analogs for the treatment of cancer
Jan, 2022

(2 years ago)

US7312237 R-PHARM US LLC Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases
Aug, 2024

(a month ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 16, 2012
Pediatric Exclusivity(PED) Apr 18, 2015
M(M-61) Oct 18, 2014

Drugs and Companies using IXABEPILONE ingredient

NCE-1 date: 18 April, 2014

Market Authorisation Date: 16 October, 2007

Dosage: INJECTABLE

How can I launch a generic of IXEMPRA KIT before it's drug patent expiration?
More Information on Dosage

IXEMPRA KIT family patents

Family Patents

31. Jevtana Kit patent expiration

Treatment: Increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering as a 3 we...

JEVTANA KIT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10583110 SANOFI AVENTIS US Antitumoral use of cabazitaxel
Oct, 2030

(6 years from now)

US10716777 SANOFI AVENTIS US Antitumoral use of cabazitaxel
Oct, 2030

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 17, 2015
M(M-201) May 17, 2020
M(M-209) Sep 14, 2020
Pediatric Exclusivity(PED) Nov 17, 2020
M(M-128) Dec 18, 2023

Drugs and Companies using CABAZITAXEL ingredient

NCE-1 date: 18 November, 2019

Market Authorisation Date: 17 June, 2010

Dosage: SOLUTION

How can I launch a generic of JEVTANA KIT before it's drug patent expiration?
More Information on Dosage

JEVTANA KIT family patents

Family Patents

32. Kisqali patent expiration

Treatment: In combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy in postmenopausal women or in men, for the treatment of hr-positive, her2-negat...

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9868739 NOVARTIS Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
Nov, 2031

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-783) Jul 18, 2021
New Indication(I-784) Jul 18, 2021
New Chemical Entity Exclusivity(NCE) Mar 13, 2022
New Patient Population(NPP) Dec 10, 2024
New Indication(I-950) Sep 17, 2027

Drugs and Companies using RIBOCICLIB SUCCINATE ingredient

NCE-1 date: 13 March, 2021

Market Authorisation Date: 13 March, 2017

Dosage: TABLET

How can I launch a generic of KISQALI before it's drug patent expiration?
More Information on Dosage

KISQALI family patents

Family Patents

33. Kisqali Femara Co-pack (copackaged) patent expiration

Treatment: As initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8962630 NOVARTIS Pyrrolopyrimidine compounds and their uses
Dec, 2029

(5 years from now)

US9416136 NOVARTIS Pyrrolopyrimidine compounds and their uses
Aug, 2029

(4 years from now)

US9868739 NOVARTIS Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
Nov, 2031

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 13, 2022
New Patient Population(NPP) Dec 10, 2024
New Indication(I-951) Sep 17, 2027

Drugs and Companies using LETROZOLE; RIBOCICLIB SUCCINATE ingredient

NCE-1 date: 13 March, 2021

Market Authorisation Date: 04 May, 2017

Dosage: TABLET

How can I launch a generic of KISQALI FEMARA CO-PACK (COPACKAGED) before it's drug patent expiration?
More Information on Dosage

KISQALI FEMARA CO-PACK (COPACKAGED) family patents

Family Patents

34. Lazanda patent expiration

Treatment: Management of breakthrough pain in patients with cancer

LAZANDA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8889176 BTCP PHARMA Method of managing or treating pain
Jan, 2024

(8 months ago)

US8216604 BTCP PHARMA Method of managing or treating pain
Oct, 2024

(11 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Jun 30, 2014

Drugs and Companies using FENTANYL CITRATE ingredient

Market Authorisation Date: 30 June, 2011

Dosage: SPRAY, METERED

More Information on Dosage

LAZANDA family patents

Family Patents

35. Lenvima patent expiration

Treatment: Method for treating thyroid carcinoma including differentiated thyroid cancer

LENVIMA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9006256 EISAI INC Antitumor agent for thyroid cancer
Jul, 2027

(2 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-734) May 13, 2019
New Chemical Entity Exclusivity(NCE) Feb 13, 2020
New Indication(I-787) Aug 15, 2021
Orphan Drug Exclusivity(ODE) Feb 13, 2022
Orphan Drug Exclusivity(ODE-87) Feb 13, 2022
New Indication(I-807) Sep 17, 2022
M(M-269) Jul 21, 2024
New Indication(I-868) Aug 10, 2024
M(M-272) Dec 19, 2024
Orphan Drug Exclusivity(ODE-196) Aug 15, 2025
M(M-14) Apr 03, 2027
Pediatric Exclusivity(PED) Oct 03, 2027

Drugs and Companies using LENVATINIB MESYLATE ingredient

NCE-1 date: 03 October, 2026

Market Authorisation Date: 13 February, 2015

Dosage: CAPSULE

How can I launch a generic of LENVIMA before it's drug patent expiration?
More Information on Dosage

LENVIMA family patents

Family Patents

36. Locametz patent expiration

Treatment: For use after radiolabeling with gallium-68, for positron emission tomography of prostate-specific membrane antigen (psma)-positive lesions in men with prostate Read More

LOCAMETZ's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11369590 NOVARTIS PSMA binding ligand-linker conjugates and methods for using
Aug, 2028

(3 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 23, 2025

Drugs and Companies using GALLIUM GA-68 GOZETOTIDE ingredient

Market Authorisation Date: 23 March, 2022

Dosage: POWDER

More Information on Dosage

LOCAMETZ family patents

Family Patents

37. Lonsurf patent expiration

Treatment: Treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan...

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5744475 TAIHO ONCOLOGY Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same
Mar, 2016

(8 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6479500 TAIHO ONCOLOGY Agents for alleviating side effects
Mar, 2020

(4 years ago)

US7799783 TAIHO ONCOLOGY Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
Dec, 2026

(2 years from now)

USRE46284 TAIHO ONCOLOGY Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
Sep, 2029

(4 years from now)

US10456399 TAIHO ONCOLOGY Method for treating cancer patients with severe renal impairment
Feb, 2037

(12 years from now)

US9943537 TAIHO ONCOLOGY Antitumor agent and antitumor effect enhancer
Sep, 2034

(9 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 22, 2020
New Indication(I-794) Feb 22, 2022
Orphan Drug Exclusivity(ODE-229) Feb 22, 2026

Drugs and Companies using TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE ingredient

NCE-1 date: 23 September, 2019

Market Authorisation Date: 22 September, 2015

Dosage: TABLET

How can I launch a generic of LONSURF before it's drug patent expiration?
More Information on Dosage

LONSURF family patents

Family Patents

38. Lorbrena patent expiration

Treatment: Treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors are anaplastic lymphoma kinase (alk)-positive as...

Can you believe LORBRENA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10420749 PFIZER Crystalline form of lorlatinib free base
Jul, 2036

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 02, 2023
New Indication(I-847) Mar 03, 2024
Orphan Drug Exclusivity(ODE-217) Nov 02, 2025
Orphan Drug Exclusivity(ODE-218) Nov 02, 2025
Orphan Drug Exclusivity(ODE-219) Nov 02, 2025
Orphan Drug Exclusivity(ODE-349) Mar 03, 2028

Drugs and Companies using LORLATINIB ingredient

NCE-1 date: 02 November, 2022

Market Authorisation Date: 02 November, 2018

Dosage: TABLET

More Information on Dosage

LORBRENA family patents

Family Patents

39. Lumakras patent expiration

Treatment: Treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fd...

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11236091 AMGEN INC Solid state forms
May, 2040

(15 years from now)

US11827635 AMGEN INC Solid state forms
May, 2040

(15 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11426404 AMGEN INC Dosing of KRAS inhibitor for treatment of cancers
Sep, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 28, 2026
ODE*(ODE*) May 28, 2028
Orphan Drug Exclusivity(ODE-352) May 28, 2028

Drugs and Companies using SOTORASIB ingredient

NCE-1 date: 28 May, 2025

Market Authorisation Date: 28 May, 2021

Dosage: TABLET

More Information on Dosage

LUMAKRAS family patents

Family Patents

40. Lupron Depot patent expiration

Treatment: Palliative treatment of prostate cancer

LUPRON DEPOT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8921326 ABBVIE ENDOCRINE INC Sustained-release composition and method for producing the same
Feb, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-132) Jun 17, 2014
New Strength(NS) Jun 17, 2014

Drugs and Companies using LEUPROLIDE ACETATE ingredient

Market Authorisation Date: 22 December, 1995

Dosage: INJECTABLE

How can I launch a generic of LUPRON DEPOT before it's drug patent expiration?
More Information on Dosage

LUPRON DEPOT family patents

Family Patents

41. Lynparza patent expiration

Treatment: Adjuvant treatment of patients with gbrca-mutated human epidermal growth factor receptor 2 (her2)-negative high risk early breast cancer who...

LYNPARZA's oppositions filed in EPO
LYNPARZA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8143241 ASTRAZENECA DNA damage repair inhibitors for treatment of cancer
Aug, 2027

(2 years from now)

US8859562 ASTRAZENECA Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer
Aug, 2031

(6 years from now)

US8912187 ASTRAZENECA Phthalazinone derivatives
Mar, 2024

(7 months ago)

US9169235 ASTRAZENECA Phthalazinone derivatives
Mar, 2024

(7 months ago)

US8071579 ASTRAZENECA DNA damage repair inhibitors for the treatment of cancer
Aug, 2027

(2 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 19, 2019
New Product(NP) Aug 17, 2020
New Indication(I-762) Jan 12, 2021
New Indication(I-776) Dec 19, 2021
Orphan Drug Exclusivity(ODE) Dec 19, 2021
Orphan Drug Exclusivity(ODE-83) Dec 19, 2021
New Indication(I-818) Dec 27, 2022
New Indication(I-831) May 08, 2023
New Indication(I-832) May 19, 2023
Orphan Drug Exclusivity(ODE-180) Aug 17, 2024
Orphan Drug Exclusivity(ODE-181) Aug 17, 2024
New Indication(I-885) Mar 11, 2025
Orphan Drug Exclusivity(ODE-226) Dec 19, 2025
New Indication(I-914) May 31, 2026
Orphan Drug Exclusivity(ODE-283) Dec 27, 2026
Orphan Drug Exclusivity(ODE-306) May 08, 2027

Drugs and Companies using OLAPARIB ingredient

NCE-1 date: 19 December, 2018

Market Authorisation Date: 19 December, 2014

Dosage: CAPSULE; TABLET

How can I launch a generic of LYNPARZA before it's drug patent expiration?
More Information on Dosage

LYNPARZA family patents

Family Patents

42. Mekinist patent expiration

Treatment: Mekinist is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with...

MEKINIST's oppositions filed in EPO
Can you believe MEKINIST received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8703781 NOVARTIS Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors
Oct, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8952018 NOVARTIS Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors
Oct, 2030

(6 years from now)

US8835443 NOVARTIS Pyrimidine compound and medical use thereof
Jun, 2025

(7 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-678) Jan 08, 2017
New Chemical Entity Exclusivity(NCE) May 29, 2018
M(M-170) Nov 20, 2018
Orphan Drug Exclusivity(ODE) May 29, 2020
Orphan Drug Exclusivity(ODE-48) May 29, 2020
New Indication(I-745) Jun 22, 2020
Orphan Drug Exclusivity(ODE-57) Jan 08, 2021
New Indication(I-778) Apr 30, 2021
New Indication(I-781) May 04, 2021
M(M-246) Oct 06, 2022
Orphan Drug Exclusivity(ODE-148) Jun 22, 2024
Orphan Drug Exclusivity(ODE-182) Apr 30, 2025
Orphan Drug Exclusivity(ODE-183) May 04, 2025
New Indication(I-895) Jun 22, 2025
Pediatric Exclusivity(PED) Sep 16, 2026
New Indication(I-908) Mar 16, 2026
New Product(NP) Mar 16, 2026
Orphan Drug Exclusivity(ODE-428) Mar 16, 2030

Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient

NCE-1 date: 22 December, 2024

Market Authorisation Date: 29 May, 2013

Dosage: TABLET

More Information on Dosage

MEKINIST family patents

Family Patents

43. Mektovi patent expiration

Treatment: Mektovi is a kinase inhibitor indicated in combination with encorafenib, for the treatment of patients with metastatic non small cell lung cancer

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9314464 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Jul, 2031

(6 years from now)

US10005761 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(5 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 27, 2023
Orphan Drug Exclusivity(ODE-194) Jun 27, 2025
New Indication(I-928) Oct 11, 2026

Drugs and Companies using BINIMETINIB ingredient

NCE-1 date: 27 June, 2022

Market Authorisation Date: 27 June, 2018

Dosage: TABLET

How can I launch a generic of MEKTOVI before it's drug patent expiration?
More Information on Dosage

MEKTOVI family patents

Family Patents

44. Nerlynx patent expiration

Treatment: Extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (her2)-positive breast cancer, to fo...

NERLYNX's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6288082 PUMA BIOTECH Substituted 3-cyanoquinolines
Sep, 2019

(5 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7982043 PUMA BIOTECH Protein tyrosine kinase enzyme inhibitors
Oct, 2025

(11 months from now)

US8790708 PUMA BIOTECH Coated tablet formulations and uses thereof
Nov, 2030

(6 years from now)

US9211291 PUMA BIOTECH Treatment regimen utilizing neratinib for breast cancer
Mar, 2030

(5 years from now)

US8518446 PUMA BIOTECH Coated tablet formulations and uses thereof
Nov, 2030

(6 years from now)

US9630946 PUMA BIOTECH Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
Oct, 2028

(4 years from now)

US10035788 PUMA BIOTECH Maleate salts of (E)-N-{4[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
Oct, 2028

(4 years from now)

US9265784 PUMA BIOTECH Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
Aug, 2029

(4 years from now)

US8669273 PUMA BIOTECH Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
Jul, 2031

(6 years from now)

US9139558 PUMA BIOTECH Maleate salts of (E)-N-{4-[3-Chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
Oct, 2028

(4 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 17, 2022
New Indication(I-823) Feb 25, 2023
New Dosing Schedule(D-182) Jun 28, 2024

Drugs and Companies using NERATINIB MALEATE ingredient

NCE-1 date: 17 July, 2021

Market Authorisation Date: 17 July, 2017

Dosage: TABLET

How can I launch a generic of NERLYNX before it's drug patent expiration?
More Information on Dosage

NERLYNX family patents

Family Patents

45. Nubeqa patent expiration

Treatment: Treatment of patients with non-metastatic castration resistant prostate cancer

NUBEQA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8975254 BAYER HEALTHCARE Androgen receptor modulating compounds
Mar, 2033

(8 years from now)

US9657003 BAYER HEALTHCARE Androgen receptor modulating compounds
Oct, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10835515 BAYER HEALTHCARE Carboxamide derivative and its diastereomers in stable crystalline form
Jan, 2036

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 30, 2024
New Indication(I-900) Aug 05, 2025

Drugs and Companies using DAROLUTAMIDE ingredient

NCE-1 date: 31 July, 2023

Market Authorisation Date: 30 July, 2019

Dosage: TABLET

More Information on Dosage

NUBEQA family patents

Family Patents

46. Onivyde patent expiration

Treatment: Treatment of pancreatic cancer; Treatment of pancreatic cancer that has progress...

ONIVYDE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8703181 IPSEN Liposomes useful for drug delivery
May, 2025

(6 months from now)

US9452162 IPSEN Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
Jun, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 22, 2018
Orphan Drug Exclusivity(ODE) Oct 22, 2022
Orphan Drug Exclusivity(ODE-99) Oct 22, 2022
New Indication(I-932) Feb 13, 2027
Orphan Drug Exclusivity(ODE-463) Feb 13, 2031

Drugs and Companies using IRINOTECAN HYDROCHLORIDE ingredient

Market Authorisation Date: 22 October, 2015

Dosage: INJECTABLE, LIPOSOMAL

More Information on Dosage

ONIVYDE family patents

Family Patents

47. Onsolis patent expiration

Treatment: Management of breakthrough pain in patients with cancer

ONSOLIS IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7579019 ADALVO Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
Jan, 2020

(4 years ago)

US9579288 ADALVO Tesofensine and beta blocker combination formulations
Jul, 2027

(2 years from now)

US9597288 ADALVO Transmucosal delivery devices with enhanced uptake
Jul, 2027

(2 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jul 16, 2012

Drugs and Companies using FENTANYL CITRATE ingredient

Market Authorisation Date: 16 July, 2009

Dosage: FILM

More Information on Dosage

ONSOLIS family patents

Family Patents

48. Orgovyx patent expiration

Treatment: Treatment of adult patients with advanced prostate cancer; Treatment of adult patients with advanced prostate

ORGOVYX's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11583526 SUMITOMO PHARMA Treatment of prostate cancer
Sep, 2037

(12 years from now)

US12097198 SUMITOMO PHARMA Treatment of prostate cancer
Sep, 2037

(12 years from now)

US8735401 SUMITOMO PHARMA Thienopyrimidine compounds and use thereof
Feb, 2024

(8 months ago)

US10449191 SUMITOMO PHARMA Treatment of prostate cancer
Sep, 2037

(12 years from now)

US10786501 SUMITOMO PHARMA Treatment of prostate cancer
Sep, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 18, 2025

Drugs and Companies using RELUGOLIX ingredient

NCE-1 date: 18 December, 2024

Market Authorisation Date: 18 December, 2020

Dosage: TABLET

More Information on Dosage

ORGOVYX family patents

Family Patents

49. Orserdu patent expiration

Treatment: Treatment of an er-positive breast cancer; Treatment of an er-positive breast cancer

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7612114 STEMLINE THERAP Selective estrogen receptor modulator
Aug, 2026

(1 year, 10 months from now)

US8399520 STEMLINE THERAP Selective estrogen receptor modulator
Dec, 2024

(2 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11819480 STEMLINE THERAP Methods for treating cancer
Nov, 2036

(12 years from now)

US10420734 STEMLINE THERAP Method of treating cancer using selective estrogen receptor modulators
Oct, 2034

(9 years from now)

US10745343 STEMLINE THERAP Polymorphic forms of RAD1901-2HCl
Jan, 2038

(13 years from now)

US10071066 STEMLINE THERAP Method of treating cancer using selective estrogen receptor modulators
Oct, 2034

(9 years from now)

US11779552 STEMLINE THERAP Method of treating cancer using selective estrogen receptor modulators
Oct, 2034

(9 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 27, 2028

Drugs and Companies using ELACESTRANT DIHYDROCHLORIDE ingredient

NCE-1 date: 27 January, 2027

Market Authorisation Date: 27 January, 2023

Dosage: TABLET

More Information on Dosage

ORSERDU family patents

Family Patents

50. Pemfexy patent expiration

Treatment: Use of pemetrexed with prior and/or repeated vitamin b12 and folic acid administration in patients with non-squamous non-small cell lung cancer

PEMFEXY's oppositions filed in EPO
PEMFEXY IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7772209 EAGLE PHARMS Antifolate combination therapies
May, 2022

(2 years ago)




Drugs and Companies using PEMETREXED ingredient

Market Authorisation Date: 08 February, 2020

Dosage: SOLUTION

More Information on Dosage

PEMFEXY family patents

Family Patents

51. Piqray patent expiration

Treatment: In combination with fulvestrant for treatment of adults with hr-positive, her-2-negative, pik3ca-mutated, advanced or metastatic breast cancer

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8227462 NOVARTIS Pyrrolidine-1,2-dicarboxamide derivatives
Apr, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 24, 2024
New Indication(I-937) Jan 18, 2027

Drugs and Companies using ALPELISIB ingredient

NCE-1 date: 25 May, 2023

Market Authorisation Date: 24 May, 2019

Dosage: TABLET

More Information on Dosage

PIQRAY family patents

Family Patents

52. Pluvicto patent expiration

Treatment: For treatment of adult patients with prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcr...

PLUVICTO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11318121 NOVARTIS PSMA binding ligand-linker conjugates and methods for using
Aug, 2028

(3 years from now)

US10406240 NOVARTIS PSMA binding ligand-linker conjugates and methods for using
Aug, 2028

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11951190 NOVARTIS Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer
Nov, 2035

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 23, 2027

Drugs and Companies using LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN ingredient

NCE-1 date: 23 March, 2026

Market Authorisation Date: 23 March, 2022

Dosage: SOLUTION

More Information on Dosage

PLUVICTO family patents

Family Patents

53. Posluma patent expiration

Treatment: Positron emission tomography (pet) of prostate-specific membrane antigen (psma) positive lesions in men with prostate cancer with suspected ...

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11413360 BLUE EARTH Dual mode radiotracer and—therapeutics
Nov, 2038

(14 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12036290 BLUE EARTH Pharmaceutical formulations
Nov, 2041

(17 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 25, 2028

Drugs and Companies using FLOTUFOLASTAT F-18 GALLIUM ingredient

NCE-1 date: 26 May, 2027

Market Authorisation Date: 25 May, 2023

Dosage: SOLUTION

More Information on Dosage

POSLUMA family patents

Family Patents

54. Pylarify patent expiration

Treatment: Method of positron emission tomography (pet) in men with prostate cancer

Can you believe PYLARIFY received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8778305 PROGENICS PHARMS INC PSMA-binding agents and uses thereof
Sep, 2030

(5 years from now)

US9861713 PROGENICS PHARMS INC PSMA-binding agents and uses thereof
Jul, 2029

(4 years from now)

US10947197 PROGENICS PHARMS INC Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPyL
Jun, 2037

(12 years from now)

US11851407 PROGENICS PHARMS INC Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPYL
Jun, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 26, 2026

Drugs and Companies using PIFLUFOLASTAT F-18 ingredient

NCE-1 date: 26 May, 2025

Market Authorisation Date: 26 May, 2021

Dosage: SOLUTION

More Information on Dosage

PYLARIFY family patents

Family Patents

55. Retevmo patent expiration

Treatment: Treating adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require s...

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10584124 LOXO ONCOL ELI LILLY Crystalline forms
Oct, 2038

(13 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10786489 LOXO ONCOL ELI LILLY Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carbonitrile
Oct, 2038

(13 years from now)

US10172851 LOXO ONCOL ELI LILLY Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Oct, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 08, 2025
Orphan Drug Exclusivity(ODE-301) May 08, 2027
Orphan Drug Exclusivity(ODE-302) May 08, 2027
Orphan Drug Exclusivity(ODE-303) May 08, 2027
New Patient Population(NPP) May 29, 2027
Orphan Drug Exclusivity(ODE-409) Sep 21, 2029
Orphan Drug Exclusivity(ODE-412) Sep 21, 2029
Orphan Drug Exclusivity(ODE-484) May 29, 2031
Orphan Drug Exclusivity(ODE-485) May 29, 2031
Orphan Drug Exclusivity(ODE-487) May 29, 2031

Drugs and Companies using SELPERCATINIB ingredient

NCE-1 date: 08 May, 2024

Market Authorisation Date: 10 April, 2024

Dosage: CAPSULE; TABLET

More Information on Dosage

RETEVMO family patents

Family Patents

56. Rezlidhia patent expiration

Treatment: A method of treating a cancer characterized by an idh1 mutation where the cancer...

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9834539 RIGEL PHARMS Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Sep, 2035

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11013733 RIGEL PHARMS Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
May, 2039

(14 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 01, 2027
Orphan Drug Exclusivity(ODE-413) Dec 01, 2029

Drugs and Companies using OLUTASIDENIB ingredient

NCE-1 date: 01 December, 2026

Market Authorisation Date: 01 December, 2022

Dosage: CAPSULE

More Information on Dosage

REZLIDHIA family patents

Family Patents

57. Rozlytrek patent expiration

Treatment: Treatment of ros1-positive non-small cell lung cancer; Treatment of colorectal cancer

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10738037 GENENTECH INC Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2037

(12 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8673893 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Jul, 2028

(3 years from now)

US10231965 GENENTECH INC Molecules for administration to ROS1 mutant cancer cells
Feb, 2035

(10 years from now)

US9255087 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Jul, 2028

(3 years from now)

US9649306 GENENTECH INC Treatment of diseases through administration of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 15, 2024
Orphan Drug Exclusivity(ODE-265) Aug 15, 2026
Orphan Drug Exclusivity(ODE-313) Aug 15, 2026
New Product(NP) Oct 20, 2026
New Patient Population(NPP) Oct 20, 2026
Orphan Drug Exclusivity(ODE-448) Oct 20, 2030

Drugs and Companies using ENTRECTINIB ingredient

NCE-1 date: 16 August, 2023

Market Authorisation Date: 15 August, 2019

Dosage: CAPSULE

More Information on Dosage

ROZLYTREK family patents

Family Patents

58. Rubraca patent expiration

Treatment: A method for treating ovarian cancer by administering rucaparib, wherein the cancer

RUBRACA's oppositions filed in EPO
RUBRACA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9861638 PHARMAAND Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one
Feb, 2031

(6 years from now)

US7351701 PHARMAAND Therapeutic compounds
Jul, 2024

(2 months ago)

US7531530 PHARMAAND Therapeutic compounds
Jul, 2024

(2 months ago)

US8071579 PHARMAAND DNA damage repair inhibitors for the treatment of cancer
Aug, 2027

(2 years from now)

US8143241 PHARMAAND DNA damage repair inhibitors for treatment of cancer
Aug, 2027

(2 years from now)

US8859562 PHARMAAND Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer
Aug, 2031

(6 years from now)

US10130636 PHARMAAND High dosage strength tablets of rucaparib
Aug, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-772) Apr 06, 2021
New Chemical Entity Exclusivity(NCE) Dec 19, 2021
New Indication(I-830) May 15, 2023
Orphan Drug Exclusivity(ODE) Dec 19, 2023
Orphan Drug Exclusivity(ODE-126) Dec 19, 2023
Orphan Drug Exclusivity(ODE-168) Apr 06, 2025

Drugs and Companies using RUCAPARIB CAMSYLATE ingredient

NCE-1 date: 19 December, 2020

Market Authorisation Date: 19 December, 2016

Dosage: TABLET

More Information on Dosage

RUBRACA family patents

Family Patents

59. Tabrecta patent expiration

Treatment: Use for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with a mesenchymal-epithelial transition (met) exon 14 ...

TABRECTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12084449 NOVARTIS PHARM Imidazotriazines and imidazopyrimidines as kinase inhibitors
Nov, 2027

(3 years from now)

US8901123 NOVARTIS PHARM Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-B][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
May, 2029

(4 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 06, 2025
Orphan Drug Exclusivity(ODE-291) May 06, 2027

Drugs and Companies using CAPMATINIB HYDROCHLORIDE ingredient

NCE-1 date: 06 May, 2024

Market Authorisation Date: 06 May, 2020

Dosage: TABLET

More Information on Dosage

TABRECTA family patents

Family Patents

60. Tafinlar patent expiration

Treatment: Tafinlar(r) is indicated, in combination with trametinib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) w...

TAFINLAR's oppositions filed in EPO
Can you believe TAFINLAR received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8703781 NOVARTIS Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors
Oct, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8952018 NOVARTIS Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors
Oct, 2030

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-678) Jan 08, 2017
New Chemical Entity Exclusivity(NCE) May 29, 2018
M(M-170) Nov 20, 2018
Orphan Drug Exclusivity(ODE) May 29, 2020
Orphan Drug Exclusivity(ODE-47) May 29, 2020
New Indication(I-745) Jun 22, 2020
Orphan Drug Exclusivity(ODE-58) Jan 09, 2021
New Indication(I-778) Apr 30, 2021
New Indication(I-781) May 04, 2021
M(M-246) Oct 06, 2022
Orphan Drug Exclusivity(ODE-147) Jun 22, 2024
Orphan Drug Exclusivity(ODE-182) Apr 30, 2025
Orphan Drug Exclusivity(ODE-183) May 04, 2025
New Indication(I-894) Jun 22, 2025
Pediatric Exclusivity(PED) Sep 16, 2026
New Indication(I-908) Mar 16, 2026
New Product(NP) Mar 16, 2026
Orphan Drug Exclusivity(ODE-428) Mar 16, 2030

Drugs and Companies using DABRAFENIB MESYLATE ingredient

NCE-1 date: 22 December, 2024

Market Authorisation Date: 29 May, 2013

Dosage: CAPSULE

More Information on Dosage

TAFINLAR family patents

Family Patents

61. Talzenna patent expiration

Treatment: Treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (brca)-mutated (gbrcam) hum...

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9820985 PFIZER Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
Jul, 2029

(4 years from now)

US10780088 PFIZER Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
Jul, 2029

(4 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 16, 2023
New Indication(I-920) Jun 20, 2026

Drugs and Companies using TALAZOPARIB TOSYLATE ingredient

NCE-1 date: 16 October, 2022

Market Authorisation Date: 20 June, 2023

Dosage: CAPSULE

More Information on Dosage

TALZENNA family patents

Family Patents

62. Tarceva patent expiration

Treatment: First-line treatment of metastatic non small-cell lung cancer (nsclc) with egfr exon 19 deletions or exon 21 (l858r) substitution mutations ...

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7087613 OSI PHARMS Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
Nov, 2020

(3 years ago)




Drug Exclusivity Drug Exclusivity Expiration
M(M-79) Sep 19, 2011
New Indication(I-624) Apr 16, 2013
New Indication(I-671) May 14, 2016
Pediatric Exclusivity(PED) Nov 14, 2016
New Dosing Schedule(D-164) May 20, 2019
M(M-181) Jun 01, 2019
M(M-190) Oct 18, 2019

Drugs and Companies using ERLOTINIB HYDROCHLORIDE ingredient

Market Authorisation Date: 18 November, 2004

Dosage: TABLET

How can I launch a generic of TARCEVA before it's drug patent expiration?
More Information on Dosage

TARCEVA family patents

Family Patents

63. Tepmetko patent expiration

Treatment: Treating a solid tumor, including lung cancer, with a met alteration(s), or stabilizing or improving symptoms associated with having a solid...

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8658643 EMD SERONO INC Pyrimidinyl pyridazinone derivatives
Jul, 2028

(3 years from now)

US8927540 EMD SERONO INC Pyridazinone derivatives
Jul, 2028

(3 years from now)

US9403799 EMD SERONO INC Pyrimidinyl-pyridazinone derivatives for treating a disease which is influenced by inhibition of met kinase
Jul, 2028

(3 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 03, 2026
Orphan Drug Exclusivity(ODE-325) Feb 03, 2028

Drugs and Companies using TEPOTINIB HYDROCHLORIDE ingredient

NCE-1 date: 03 February, 2025

Market Authorisation Date: 03 February, 2021

Dosage: TABLET

More Information on Dosage

TEPMETKO family patents

Family Patents

64. Tibsovo patent expiration

Treatment: A method of treating a cancer characterized by an idh1 mutation wherein the cancer

Can you believe TIBSOVO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9474779 SERVIER Therapeutically active compositions and their methods of use
Aug, 2033

(8 years from now)

US9850277 SERVIER Therapeutically active compositions and their methods of use
Jan, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11667673 SERVIER Therapeutically active compounds and their methods of use
Jan, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-816) May 02, 2022
New Chemical Entity Exclusivity(NCE) Jul 20, 2023
New Indication(I-875) Aug 25, 2024
New Indication(I-893) May 25, 2025
Orphan Drug Exclusivity(ODE-203) Jul 20, 2025
Orphan Drug Exclusivity(ODE-242) May 02, 2026
New Indication(I-924) Oct 24, 2026
Orphan Drug Exclusivity(ODE-368) Aug 25, 2028
Orphan Drug Exclusivity(ODE-447) Oct 24, 2030

Drugs and Companies using IVOSIDENIB ingredient

NCE-1 date: 20 July, 2022

Market Authorisation Date: 20 July, 2018

Dosage: TABLET

How can I launch a generic of TIBSOVO before it's drug patent expiration?
More Information on Dosage

TIBSOVO family patents

Family Patents

65. Truqap patent expiration

Treatment: Treatment with fulvestrant of hr-pos. her2-neg. locally advanced or metastatic breast cancer with pik3ca/akt1/pten-alteration(s) following p...

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8101623 ASTRAZENECA Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor
Mar, 2030

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11760760 ASTRAZENECA Protein kinase B inhibitors
Oct, 2028

(3 years from now)

US10654855 ASTRAZENECA Protein kinase B inhibitors
Oct, 2028

(3 years from now)

US10039766 ASTRAZENECA Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d] pyrimidin-4-y1) piperidine-4-carboxamide
Apr, 2033

(8 years from now)

US8809336 ASTRAZENECA Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors
Oct, 2025

(1 year, 10 days from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 16, 2028

Drugs and Companies using CAPIVASERTIB ingredient

NCE-1 date: 17 November, 2027

Market Authorisation Date: 16 November, 2023

Dosage: TABLET

More Information on Dosage

TRUQAP family patents

Family Patents

66. Tukysa patent expiration

Treatment: Treatment of breast cancer including her2 (erbb2)-positive or -overexpressing breast ca...

TUKYSA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7452895 SEAGEN Quinazoline analogs as receptor tyrosine kinase inhibitors
Nov, 2024

(a month from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11504370 SEAGEN Treatment of brain cancer
Mar, 2033

(8 years from now)

US11666572 SEAGEN Treatment of HER2 positive cancers
Apr, 2038

(13 years from now)

US12048698 SEAGEN Treatment of HER2 positive cancers
Apr, 2038

(13 years from now)

US9457093 SEAGEN Solid dispersions of a ERB2 (HER2) inhibitor
Oct, 2032

(7 years from now)

US9693989 SEAGEN N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
May, 2027

(2 years from now)

US11207324 SEAGEN Treatment of HER2 positive cancers
Apr, 2038

(13 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 17, 2025
New Indication(I-906) Jan 19, 2026
Orphan Drug Exclusivity(ODE-309) Apr 17, 2027
Orphan Drug Exclusivity(ODE-422) Jan 19, 2030

Drugs and Companies using TUCATINIB ingredient

NCE-1 date: 17 April, 2024

Market Authorisation Date: 17 April, 2020

Dosage: TABLET

More Information on Dosage

TUKYSA family patents

Family Patents

67. Varubi patent expiration

Treatment: Prevention of delayed nausea and vomiting associated with emetogenic cancer chemotherapy

VARUBI's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7049230 TERSERA Method of forming a contact plug in a semiconductor device
Dec, 2023

(10 months ago)

US7049320 TERSERA NK1 antagonists
Aug, 2028

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8796299 TERSERA NK1 antagonists
Dec, 2022

(1 year, 9 months ago)

US8470842 TERSERA Hydrochloride salts of 8-[{1-(3,5-Bis-trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
Jan, 2029

(4 years from now)

US8404702 TERSERA Pharmaceutical formulations:salts of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxymethyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
Apr, 2027

(2 years from now)

US9101615 TERSERA Intravenous formulations of neurokinin-1 antagonists
Jul, 2032

(7 years from now)

US7981905 TERSERA Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-Ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
Apr, 2027

(2 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 01, 2020

Drugs and Companies using ROLAPITANT HYDROCHLORIDE ingredient

NCE-1 date: 02 September, 2019

Market Authorisation Date: 25 October, 2017

Dosage: EMULSION; TABLET

More Information on Dosage

VARUBI family patents

Family Patents

68. Venclexta patent expiration

Treatment: Treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic leukemia (sll) in combination with a ga101 antibody such as obinutuzumab for one or more dosing periods, wherei...

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9539251 ABBVIE Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor
Sep, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 11, 2021
New Indication(I-782) Jun 08, 2021
M(M-228) Jun 08, 2021
New Indication(I-789) Nov 21, 2021
New Indication(I-795) May 15, 2022
Orphan Drug Exclusivity(ODE) Apr 11, 2023
Orphan Drug Exclusivity(ODE-114) Apr 11, 2023
M(M-265) Oct 16, 2023
Orphan Drug Exclusivity(ODE-185) Jun 08, 2025
Orphan Drug Exclusivity(ODE-211) Nov 21, 2025
Orphan Drug Exclusivity(ODE-239) May 15, 2026

Drugs and Companies using VENETOCLAX ingredient

NCE-1 date: 11 April, 2020

Market Authorisation Date: 11 April, 2016

Dosage: TABLET

How can I launch a generic of VENCLEXTA before it's drug patent expiration?